Adhesion Molecules

Adhesion molecules on immune cells: role in the pathogenesis of MS, risk for opportunistic infections and impact of immunotherapies

Project Description:

  • Unravel pathogenesis of MS by evaluation of adhesion molecules on immune cells in peripheral blood and CSF
  • Impact of different immunotherapies on adhesion molecules
  • Assessment of risk for opportunistic infection including PML and VZV
  • Monitoring of immune cell distribution and adhesion molecule expression for individualized treatment concepts

 

Recent Publications:

  • Recent poster presentation at ECTRIMS 2017: “The immune receptor expression pattern in peripheral-blood associated with JCV seropositivity in patients with multiple sclerosis is not affected by natalizumab”
  • Harrer A, Wipfler P, Pilz G, Oppermann K, Haschke-Becher E, Afazel S, Kraus J, Trinka E, Sellner J. Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod. Int J Mol Sci. 2015 Sep 10;16(9):21832-45.
  • Harrer A, Pilz G, Wipfler P, Oppermann K, Sellner J, Hitzl W, Haschke-Becher E, Afazel S, Rispens T, van der Kleij D, Trinka E, Kraus J. High interindividual variability in the CD4/CD8 T cell ratio and natalizumab concentration levels in the cerebrospinal fluid of patients with multiple sclerosis. Clin Exp Immunol.2015 Jun;180(3):383-92.
  • Wipfler P, Harrer A, Pilz G, Oppermann K, Afazel S, Haschke-Becher E, Sellner J, Trinka E, Kraus J. Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal? Acta Neurol Scand. 2014 Mar;129(3):e12-5.
  • Sellner J, Koczi W, Harrer A, Oppermann K, Obregon-Castrillo E, Pilz G, Wipfler P, Afazel S, Haschke-Becher E, Trinka E, Kraus J. Glatiramer acetate attenuates the pro-migratory profile of adhesion molecules on various immune cell subsets in multiple sclerosis. Clin Exp Immunol. 2013 Sep;173(3):381-9.
  • Harrer A, Pilz G, Einhaeupl M, Oppermann K, Hitzl W, Wipfler P, Sellner J, Golaszewski S, Afazel S, Haschke-Becher E, Trinka E, Kraus J. Lymphocyte subsets show different response patterns to in vivo bound natalizumab--a flow cytometric study on patients with multiple sclerosis. PLoS One. 2012;7(2):e31784.

 

Previous Funding: Swiss MS society, Bayer, Teva, Merck

Current Funding: Biogen

Project Lead

Johann  Sellner

Assoc. Prof. DDr.

Johann Sellner

Team Member

Andrea Harrer

Andrea Harrer

Team Member

Tobias Moser

Dr.

Tobias Moser

Team Member

Katrin Oppermann

Mag.

Katrin Oppermann

Gemeinnützige Salzburger Landeskliniken Betriebsgesellschaft mbH | Müllner Hauptstraße 48 | A-5020 Salzburg
Telefon: +43 (0)5 7255-0 | Fax: +43 (0)5 7255-20199 | © 2013-2018
Letzte Änderung: 06.11.2018 Impressum Datenschutz AGB
x schließen